{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23(1)"],"submitter":["Kanehira N"],"pubmed_abstract":["<h4>Background</h4>Boron neutron capture therapy (BNCT) is a molecularly targeted chemoradiation modality that relies on boron delivery agents such as p-borophenylalanine (BPA), which require LAT1 (L-type amino acid transporter 1) for tumor uptake. However, the limited efficacy of BPA in LAT1-low tumors restricts its therapeutic scope. To address this limitation, we developed a tumor marker-guided BNCT strategy targeting cancers overexpressing the clinically validated glycan biomarker CA19-9.<h4>Methods</h4>We conducted transcriptomic analyses using The Cancer Genome Atlas (TCGA) datasets to identify LAT1-low cancers with high CA19-9 expression. These analyses revealed elevated expression of fucosyltransferase 3 (FUT3), which underlies CA19-9 biosynthesis, in pancreatic, biliary, and ovari"],"journal":["Journal of translational medicine"],"pagination":["1387"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12683832"],"repository":["biostudies-literature"],"pubmed_title":["Tumor marker-guided precision BNCT for CA19-9-positive cancers: a new paradigm in molecularly targeted chemoradiation therapy."],"pmcid":["PMC12683832"],"pubmed_authors":["Shigeyasu K","Suzuki M","Fujita T","Fujimoto T","Gotoh K","Sakurai Y","Takarada T","Kamei K","Tajima T","Osone T","Michiue H","Nagahisa N","Kanehira N","Fujiwara T","Kondo N","Morihara A","Takaguchi Y","Teraishi F","Kitamatsu M"],"additional_accession":[]},"is_claimable":false,"name":"Tumor marker-guided precision BNCT for CA19-9-positive cancers: a new paradigm in molecularly targeted chemoradiation therapy.","description":"<h4>Background</h4>Boron neutron capture therapy (BNCT) is a molecularly targeted chemoradiation modality that relies on boron delivery agents such as p-borophenylalanine (BPA), which require LAT1 (L-type amino acid transporter 1) for tumor uptake. However, the limited efficacy of BPA in LAT1-low tumors restricts its therapeutic scope. To address this limitation, we developed a tumor marker-guided BNCT strategy targeting cancers overexpressing the clinically validated glycan biomarker CA19-9.<h4>Methods</h4>We conducted transcriptomic analyses using The Cancer Genome Atlas (TCGA) datasets to identify LAT1-low cancers with high CA19-9 expression. These analyses revealed elevated expression of fucosyltransferase 3 (FUT3), which underlies CA19-9 biosynthesis, in pancreatic, biliary, and ovari","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-07T03:13:46.642Z","creation":"2026-06-07T03:07:13.341Z"},"accession":"S-EPMC12683832","cross_references":{"pubmed":["41361823"],"doi":["10.1186/s12967-025-07349-7"]}}